Drug intelligence / Profile preview

SRB1

Development stage: Unknown
Lead developer: SunRock Biopharma
Modality: Antibody-Based Therapeutics

Overview

SRB1 is an investigational antibody drug developed by Sunrock Biopharma. It acts as an antagonist of the C-C chemokine receptor type 9 (CCR9), a target implicated in certain hematologic and solid tumors. By blocking CCR9, SRB1 may inhibit tumor cell migration and proliferation associated with this receptor. The drug is currently at the IND (Investigational New Drug) application stage for indications including hematologic neoplasms and solid tumors[3].

Targets

CCR9 (C-C chemokine receptor type 9)

Beyond the preview

Go deeper on SRB1.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SRB1.

Explore the full profile